Kiyoshi Ando

15.8k total citations · 2 hit papers
342 papers, 9.9k citations indexed

About

Kiyoshi Ando is a scholar working on Hematology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Kiyoshi Ando has authored 342 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Hematology, 106 papers in Pathology and Forensic Medicine and 93 papers in Genetics. Recurrent topics in Kiyoshi Ando's work include Lymphoma Diagnosis and Treatment (85 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Hematopoietic Stem Cell Transplantation (42 papers). Kiyoshi Ando is often cited by papers focused on Lymphoma Diagnosis and Treatment (85 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Hematopoietic Stem Cell Transplantation (42 papers). Kiyoshi Ando collaborates with scholars based in Japan, United States and United Kingdom. Kiyoshi Ando's co-authors include Tomomitsu Hotta, Shunichi Kato, Daisuke Sakai, Joji Mochida, Yoshihiko Nakamura, Takashi Yahata, Tomoko Nakai, Hiroshi Kawada, Yukari Muguruma and Toru Iwashina and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Kiyoshi Ando

331 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

2017 461 citations Kiyoshi Ando et al. profile →
Exhaustion of nucleus pulposus progenitor cells with ageing and degeneration of the intervertebral disc

2012 365 citations Yoshihiko Nakamura, Shunichi Kato et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kiyoshi Ando Japan	48	3.1k	2.8k	2.3k	2.3k	2.1k	342	9.9k
Tadashi Yoshino Japan	54	4.4k 1.4×	2.4k 0.9×	1.3k 0.6×	3.5k 1.6×	2.7k 1.3×	524	12.6k
Costantino Pitzalis United Kingdom	65	848 0.3×	3.3k 1.2×	978 0.4×	2.2k 1.0×	6.2k 3.0×	334	14.2k
Susumu Ikehara Japan	54	728 0.2×	4.0k 1.4×	2.2k 1.0×	1.8k 0.8×	7.7k 3.7×	398	15.1k
Xu Cao United States	63	1.0k 0.3×	7.5k 2.7×	1.7k 0.7×	2.5k 1.1×	1.0k 0.5×	192	13.6k
Renate E. Gay Switzerland	65	1.9k 0.6×	5.5k 1.9×	506 0.2×	2.1k 0.9×	3.5k 1.7×	174	13.4k
Lingyun Sun China	55	816 0.3×	3.0k 1.1×	3.9k 1.7×	1.1k 0.5×	2.9k 1.4×	243	10.3k
Chi‐Chao Chan United States	71	1.7k 0.6×	4.7k 1.7×	569 0.2×	1.9k 0.8×	4.7k 2.2×	397	18.4k
Beatrice Nico Italy	59	654 0.2×	6.0k 2.1×	870 0.4×	2.0k 0.9×	1.8k 0.9×	236	10.8k
Floris P. J. G. Lafeber Netherlands	56	535 0.2×	1.8k 0.6×	872 0.4×	753 0.3×	1.9k 0.9×	196	11.3k
Natalie A. Sims Australia	63	600 0.2×	7.6k 2.7×	771 0.3×	4.6k 2.1×	1.9k 0.9×	206	13.0k

Countries citing papers authored by Kiyoshi Ando

Since Specialization

Citations

This map shows the geographic impact of Kiyoshi Ando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiyoshi Ando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiyoshi Ando more than expected).

Fields of papers citing papers by Kiyoshi Ando

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kiyoshi Ando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiyoshi Ando. The network helps show where Kiyoshi Ando may publish in the future.

Co-authorship network of co-authors of Kiyoshi Ando

This figure shows the co-authorship network connecting the top 25 collaborators of Kiyoshi Ando. A scholar is included among the top collaborators of Kiyoshi Ando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kiyoshi Ando. Kiyoshi Ando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suzuki, Tomotaka, Ryunosuke Machida, Kazuyuki Shimada, et al.. (2025). Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601. PubMed. 2(2). 100077–100077.

Ishida, Tadao, Kiyoshi Ando, Rikio Suzuki, et al.. (2023). Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. International Journal of Hematology. 117(5). 729–737. 15 indexed citations

Ishiyama, Ken, Yuji Yonemura, Tatsuya Kawaguchi, et al.. (2023). A longitudinal analysis of paroxysmal nocturnal haemoglobinuria‐type cells in patients with bone marrow failure: Results of a prospective multi‐centre study in Japan. British Journal of Haematology. 203(3). 468–476. 1 indexed citations

Harada, Kaito, Makoto Onizuka, Ryujiro Hara, et al.. (2022). Risk factors for lower respiratory tract disease and outcomes in allogeneic hematopoietic stem cell transplantation recipients with influenza virus infection. Journal of Infection and Chemotherapy. 28(9). 1279–1285.

Hirano, Ken-ichi, Hiroyuki Hosokawa, Yusuke Endo, et al.. (2021). LMO2 is essential to maintain the ability of progenitors to differentiate into T-cell lineage in mice. eLife. 10. 9 indexed citations

Hara, Ryujiro, Makoto Onizuka, Eri Kikkawa, et al.. (2021). Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of Hematology. 100(10). 2479–2486. 3 indexed citations

Hara, Ryujiro, Hiroshi Kawada, Yara Yukie Kikuti, et al.. (2021). A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor. International Journal of Hematology. 113(4). 606–610. 3 indexed citations

Izutsu, Koji, Kiyoshi Ando, Daisuke Ennishi, et al.. (2021). Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study. Cancer Science. 112(6). 2405–2415. 8 indexed citations

Morita, Yasuyoshi, Takayuki Ikezoe, Kiyoshi Ando, et al.. (2020). Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML). Blood. 136(Supplement 1). 34–35.

10.

Imai, Jin, Takashi Yahata, Hitoshi Ichikawa, et al.. (2020). Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice. Intestinal Research. 18(2). 219–228. 23 indexed citations

11.

Onizuka, Makoto, Jun Amaki, Shinichiro Machida, et al.. (2019). Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide. PubMed. 2(1). 1–4. 2 indexed citations

12.

Iida, Shinsuke, Takashi Watanabe, Morio Matsumoto, et al.. (2019). Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. Cancer Science. 110(9). 2924–2932. 6 indexed citations

13.

Iida, Shinsuke, Masashi Wakabayashi, Kunihiro Tsukasaki, et al.. (2018). Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Cancer Science. 109(5). 1552–1561. 5 indexed citations

14.

Ando, Kiyoshi, Michinori Ogura, Toshiki Uchida, et al.. (2018). E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I study. Cancer Science. 109(3). 794–802. 25 indexed citations

15.

Kawamata, Toyotaka, Jun Lü, Tadayuki Sato, et al.. (2012). Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. Blood. 119(13). 3123–3127. 5 indexed citations

16.

Mabuchi, Tomotaka, et al.. (2012). Random skin biopsy of intravascular large B-cell lymphoma: a case report.. PubMed. 37(3). 75–6. 9 indexed citations

17.

Watanabe, Takashi, Kensei Tobinai, Taro Shibata, et al.. (2011). Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial. Journal of Clinical Oncology. 29(30). 3990–3998. 45 indexed citations

18.

Yahata, Takashi, Yukari Muguruma, Sheng Yin, et al.. (2008). Quiescent Human Hematopoietic Stem Cells in the Bone Marrow Niches Organize the Hierarchical Structure of Hematopoiesis. Stem Cells. 26(12). 3228–3236. 35 indexed citations

19.

Fujita, Jun, Mitsuharu Mori, Hiroshi Kawada, et al.. (2007). Administration of Granulocyte Colony-Stimulating Factor After Myocardial Infarction Enhances the Recruitment of Hematopoietic Stem Cell-Derived Myofibroblasts and Contributes to Cardiac Repair. Stem Cells. 25(11). 2750–2759. 66 indexed citations

20.

Muguruma, Yukari, Morayma Reyes, Yoshihiko Nakamura, et al.. (2003). In vivo and in vitro differentiation of myocytes from human bone marrow–derived multipotent progenitor cells. Experimental Hematology. 31(12). 1323–1330. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact